Benitec Biopharma Inc.
Description
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
About
CEO
Dr. Jerel A. Banks M.D., Ph.D.
Employees
16
Instrument type
Depositary Receipt
Sector
Healthcare
Industry
Biotechnology
MIC code
XNCM
Address
3940 Trust Way, Hayward, CA 94545, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 12, 2025 | — | — | — | — |
| Sep 24, 2025 | — | — | — | — |
| May 12, 2025 | — | — | — | — |
| Feb 11, 2025 | — | — | — | — |
| Nov 15, 2024 | -0.55 | -0.48 | 0.07 | -12.73% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Current Year
(Jun 2025)
|
Next Year
(Jun 2026)
|
||
|---|---|---|---|---|
| Number of analysts | — | 0 | 0 | 0 |
| Average estimate | — | 0.00 | 0.00 | 0.00 |
| Low estimate | — | 0.00 | 0.00 | 0.00 |
| High estimate | — | 0.00 | 0.00 | 0.00 |
| Last year EPS | — | — | — | — |
[stock_revenue_estimate]
Growth estimates
Current qtr
—
Next qtr. (Mar 2025)
—
Current year (Jun 2025)
—
Next year (Jun 2026)
—
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Fiscal date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Total reported revenue | — | 75,000 | 73,000 | 59,000 | 97,000 |
| Cost of revenue | — | — | 9,000 | 123,000 | -185,000 |
| Gross profit | — | 75,000 | 64,000 | -64,000 | 282,000 |
| Operating expense | |||||
| Research & development | 15.61M | 12.77M | 11.27M | 7.02M | 3.00M |
| Selling general and admin | 6.99M | 6.38M | 6.65M | 6.51M | 5.57M |
| Other operating expenses | -108,000 | — | 9,000 | 123,000 | -190,000 |
| Operating income | -22.49M | -19.08M | -17.85M | -13.60M | -8.28M |
| Non operating interest income | |||||
| Income | — | — | — | -6,000 | 62,000 |
| Expense | — | 33,000 | 32,000 | 6,000 | — |
| Other income expense | -165,000 | -448,000 | -322,000 | -280,000 | -55,000 |
| Pretax income | -21.75M | -19.56M | -18.21M | -13.88M | -8.27M |
| Tax provision | — | — | — | — | — |
| Net income | -21.75M | -19.56M | -18.21M | -13.88M | -8.27M |
| Basic EPS | -5.51 | -14.12 | -37.91 | -54.91 | -137.70 |
| Diluted EPS | -5.51 | -14.12 | -37.91 | -54.91 | -137.70 |
| Basic average shares | 4.06M | 1.39M | 480,687 | 252,671 | 60,070 |
| Diluted average shares | 4.06M | 1.39M | 480,687 | 252,671 | 60,070 |
| EBITDA | -22.19M | -18.28M | -17.54M | -13.14M | -7.82M |
| Net income from continuing op. | -21.75M | -19.56M | -18.21M | -13.88M | -8.27M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | 619,000 | — | — | — | — |
Balance sheet
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Fiscal date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Total assets | 52.21M | 4.46M | 5.97M | 21.38M | 11.59M |
| Current assets | |||||
| Cash | 50.87M | 2.48M | 4.06M | 19.77M | 5.23M |
| Cash equivalents | — | — | — | — | 4.57M |
| Cash and cash equivalents | 50.87M | 2.48M | 4.06M | 19.77M | 9.80M |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | 229,000 | 55,000 | 3,000 | 25,000 | 59,000 |
| Other receivables | — | — | — | — | 59,000 |
| Inventory | — | — | — | — | — |
| Prepaid assets | — | — | 741,000 | 799,000 | 948,000 |
| Restricted cash | 63,000 | 13,000 | 14,000 | 15,000 | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 516,000 | 1.18M | 741,000 | 799,000 | 1,000 |
| Non current assets | |||||
| Properties | 1.52M | 1.34M | 1.34M | 1.33M | 1.11M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 38,000 | 38,000 | 37,000 | 40,000 | 37,000 |
| Construction in progress | — | — | — | — | — |
| Leases | 24,000 | 24,000 | 24,000 | 24,000 | 24,000 |
| Accumulated depreciation | -1.40M | -1.32M | -1.18M | -1.02M | -796,000 |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 62,000 | 97,000 | 135,000 | 185,000 | — |
| Total liabilities | 4.96M | 4.26M | 3.09M | 1.37M | 1.35M |
| Current liabilities | |||||
| Accounts payable | 1.35M | 1.14M | 422,000 | 274,000 | 282,000 |
| Accrued expenses | 2.68M | 2.02M | 1.39M | 491,000 | 258,000 |
| Short term debt | 284,000 | 275,000 | 252,000 | 213,000 | 192,000 |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | 475,000 | 472,000 | 400,000 | 276,000 | 203,000 |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | — | 284,000 | 559,000 | — | 213,000 |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | — | — | — | — | — |
| Shareholders equity | |||||
| Common stock | 1,000 | — | — | 1,000 | — |
| Retained earnings | -190.26M | -167.89M | -148.33M | -130.12M | -116.64M |
| Other shareholders equity | -892,000 | -830,000 | -1.25M | -1.46M | -1.95M |
| Total shareholders equity | 47.25M | 202,000 | 2.88M | 20.01M | 10.24M |
| Additional paid in capital | 238.40M | 168.92M | 152.45M | 151.58M | 128.83M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||
| Net Income | -21.75M | -19.56M | -18.21M | -13.88M | -8.27M | 2.61M | — | — | — | — | — | — |
| Depreciation | 343,000 | 381,000 | 392,000 | 424,000 | 374,000 | 158,000 | — | 134,778 | — | — | — | — |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 830,000 | 452,000 | 870,000 | 634,000 | 237,000 | 672,000 | — | 239,744 | — | — | — | — |
| Other Non-Cash Items | — | — | — | — | — | — | — | -2.78M | — | — | — | — |
| Accounts Receivable | -176,000 | -50,000 | 1,000 | 28,000 | 2.40M | 607,000 | — | 505,575 | — | — | — | — |
| Accounts Payable | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -275,000 | -179,000 | -116,000 | -71,000 | -574,000 | -24,000 | — | -99,376 | — | — | — | — |
| Operating Cash Flow | -21.03M | -18.96M | -17.06M | -12.87M | -5.84M | 4.02M | — | -2.00M | — | — | — | — |
| Investing Activities | ||||||||||||
| Capital Expenditures | -179,000 | -1,000 | -13,000 | -221,000 | -94,000 | -248,440 | -36,956 | -81,615 | -158,628 | -240,573 | -295,305 | -18,137 |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | — | — | — | — | — | — | — | -81,364 | — | — | — | — |
| Sale of Investments | — | — | — | — | — | — | — | — | — | — | — | — |
| Investing Cash Flow | -179,000 | -1,000 | -13,000 | -221,000 | -94,000 | -248,440 | -67,068 | -225,503 | -158,628 | -240,573 | -295,305 | -18,137 |
| Financing Activities | ||||||||||||
| Long-Term Debt Issuance | — | — | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | -5.89M | -1.87M | — | -3.23M | -480,000 | — | -142,807 | -63,478 | -905,388 | -158,635 | -194,725 | — |
| Financing Cash Flow | 68.03M | 16.02M | — | 22.52M | 1.77M | — | 3.88M | 3.79M | 8.12M | 24,772 | 30,408 | 22.15M |
| Other Cash Details | ||||||||||||
| End Cash Position | 50.93M | 2.49M | 4.08M | 19.78M | 9.80M | 9.76M | 7.34M | 8.29M | 8.46M | 10.38M | 12.74M | 17.77M |
| Income Tax Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -19.58M | -18.01M | -15.91M | -13.05M | -7.63M | 2.72M | -4.51M | -4.04M | -9.53M | -4.86M | -5.96M | -5.27M |
Error: Invalid format in Holders JSON file.
Article
Why You Shouldn't Bet Against Benitec Biopharma (BNTC) Stock
Benitec Biopharma (BNTC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Jan 13, 2025
Article
Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why
Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Dec 25, 2024
Article
Wall Street Analysts See an 113.71% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High?
The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 113.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Dec 9, 2024
